InMed Pharmaceuticals (INM) Receivables - Net (2020 - 2025)

InMed Pharmaceuticals has reported Receivables - Net for 6 years, with the latest figure at $182967.0 in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 30.32% year-over-year to $182967.0; the trailing twelve-month figure through Dec 2025 stood at $182967.0 (down 30.32% YoY), and the FY2025 full-year result was $2.0 million, up 5526.41% from the prior year.
• Receivables - Net for Q4 2025 stood at $182967.0, down from $343469.0 in the prior quarter.
• The five-year high for Receivables - Net was $465104.0 in Q2 2025, with the low at $11919.0 in Q2 2021.
• Historically, Receivables - Net has averaged $147671.6 across 5 years, with a median of $76100.5 in 2022.
• Annual changes were most pronounced in 2021 — Receivables - Net tumbled 73.71% — and 2025, when it surged 1240.36%.
• InMed Pharmaceuticals' Receivables - Net stood at $50304.0 in 2021, then soared by 62.31% to $81647.0 in 2022, then fell by 18.21% to $66775.0 in 2023, then surged by 293.21% to $262569.0 in 2024, then plunged by 30.32% to $182967.0 in 2025.
• The last three Receivables - Net figures came in at $182967.0 (Q4 2025), $343469.0 (Q3 2025), and $465104.0 (Q2 2025), per Business Quant data.